SSG
CRBP icon

Summit Securities Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Summit Securities Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$385 Buy
+41
New +$345 ﹤0.01% 1004

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Summit Securities Group's CRBP Position: Q1 2026 in Review

Summit Securities Group opened a new position in Corbus Pharmaceuticals (CRBP) in Q1 2026: 41 shares worth $385. The stake represents ﹤0.01% of the portfolio and ranks #1004 among its holdings.

107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Summit Securities Group held 41 shares of Corbus Pharmaceuticals worth $385 as of Q1 2026.
  • Corbus Pharmaceuticals was a new Summit Securities Group position in Q1 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of Summit Securities Group's portfolio in Q1 2026, its #1004 holding.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.